Study guide

7.1 Iodine and Indium Diagnostic Agents

Certified Nuclear Medicine Technologist CNMT

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current CNMT Exam Facts 1.2 How to Use This Guide

2 Radiation Physics Fundamentals

2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles

3 Biological Effects & ALARA

3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring

4 NRC & Regulatory Compliance

4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records

5 Generators & Kit Preparation

5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control

6 Tc-99m Diagnostic Agents

6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells

7 Non-Tc Diagnostic & PET Agents

7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents

8 Therapeutics, Adjuncts & Administration

8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents

9 Non-Imaging Instrumentation

9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment

10 Imaging Systems & Quality Control

10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization

11 Pulmonary, Bone, Oncology & Infection Imaging

11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures

12 Renal, Endocrine & Hematopoietic Imaging

12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique

13 Cardiovascular Procedures

13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing

14 GI, CNS, Therapy & Hybrid CT Procedures

14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency

15 Patient Care & Clinical Workflow

15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis

7.1 Iodine and Indium Diagnostic Agents

Key Takeaways Explain This Topic AI

I-123 NaI (t½ ≈ 13.2 h, 159 keV) is preferred for diagnostic thyroid imaging; I-131 NaI (t½ ≈ 8.0 d, 364 keV + β−) is used for uptake and whole-body thyroid-cancer surveys at diagnostic activities

I-123 MIBG (AdreView®) is a norepinephrine analog for pheochromocytoma/neuroblastoma imaging; give thyroid blockade and hold interfering catecholamine-active meds per protocol

I-123 ioflupane (DaTscan®) binds striatal dopamine transporters for Parkinsonian syndrome evaluation; require thyroid blockade and hold cocaine, amphetamines, and selected dopaminergic drugs

In-111 (t½ ≈ 2.8 d; principal gammas ≈ 171 and 245 keV) labels WBCs (oxine), supports cisternography (DTPA), and forms In-111 pentetreotide (Octreoscan®) for somatostatin-receptor imaging

Key traps: confusing diagnostic vs therapeutic iodine activities; skipping thyroid blockade for free iodide/MIBG/DaTscan; wrong med holds that produce false-negative DaTscan or MIBG studies

Last updated: August 2026

7.1 Iodine and Indium Diagnostic Agents

Quick Answer: I-123 NaI (13.2 h, 159 keV) → diagnostic thyroid imaging. I-131 NaI (8 d, 364 keV + β−) → uptake and diagnostic whole-body surveys (therapy is higher activity). I-123 MIBG → NET/sympathetic tumors with thyroid blockade . I-123 ioflupane (DaTscan®) → striatal DAT SPECT with med holds. In-111 (2.8 d; 171/245 keV) → WBCs, DTPA cisternography, pentetreotide (Octreoscan®) .

Non-technetium single-photon agents still fill high-yield CNMT slots: thyroid physiology, neuroendocrine/sympathetic imaging, infection cell labeling, CSF studies, and receptor SPECT. Learn each agent as half-life + energy + mechanism + indication + prep trap .

Radioiodine Sodium Iodide: I-123 vs I-131 (Diagnostic)

Both chemical forms are NaI . The sodium-iodide symporter traps iodide in thyroid follicular cells; organification incorporates iodine into thyroid hormone pathways. That is why free iodide also concentrates in salivary glands and can appear in stomach .

  • Feature I-123 sodium iodide I-131 sodium iodide (diagnostic use)
  • Half-life ≈ 13.2 hours ≈ 8.0 days
  • Primary photons 159 keV gamma 364 keV gamma (+ β− emission)
  • Decay Electron capture β− decay

Typical diagnostic roles Thyroid imaging and uptake Uptake measurements; diagnostic whole-body scan after thyroidectomy for cancer staging/follow-up

Why choose Better imaging energy for gamma cameras; lower patient dose for morphology Longer half-life suits delayed whole-body surveys; β component matters more for therapy

Diagnostic adult activities (order-of-magnitude teaching values; follow package insert/lab protocol):

Study Agent Approximate activity

Thyroid scan / uptake (imaging preference) I-123 Often ~200–400 µCi (≈7–15 MBq) oral for scan (uptake doses may be lower)

Thyroid uptake only I-123 or low-activity I-131 I-131 classic uptake often tens of µCi

Diagnostic whole-body scan (thyroid cancer) I-131 Often 1–5 mCi range (protocol/regulatory dependent)— not a therapy dose

Therapy I-131 activities (ablation/treatment) are much higher (tens to hundreds of mCi) and belong with written-directive rules—do not mix “scan dose” with “treatment dose” on exam stems.

Patient prep (thyroid radioiodine): hold antithyroid drugs, levothyroxine/liothyronine, and recent iodinated contrast per protocol; low-iodine diet may be ordered before cancer surveys; document pregnancy status; counsel on radiation precautions proportional to activity. Recent IV contrast or amiodarone can suppress uptake for weeks to months.

I-123 MIBG (Iobenguane, AdreView®)

Mechanism: MIBG is a guanethidine/norepinephrine analog . It is taken up by the norepinephrine transporter (NET) into adrenergic tissues and stored in neurosecretory granules—mapping pheochromocytoma, paraganglioma, neuroblastoma , and other NET-positive sympathetic tumors (and selected cardiac sympathetic innervation protocols).

  • Item Teaching points
  • Nuclide I-123 (13.2 h, 159 keV)
  • Admin IV (slow; follow insert for infusion precautions)
  • Typical adult activity Often ~10 mCi (370 MBq) order of magnitude
  • Imaging Planar ± SPECT at ~24 h (sometimes earlier/later views)

Thyroid blockade Required —SSKI, Lugol’s, or potassium perchlorate per protocol to block free iodide uptake in thyroid

Medication holds: many catecholamine-active drugs reduce MIBG uptake (classic lists include certain tricyclic antidepressants, labetalol, some sympathomimetics, cocaine , and others—use the current package insert list). Missing a hold → false-negative tumor study. Free iodide without blockade → unwanted thyroid dose and confusing neck activity.

I-123 Ioflupane (DaTscan®)

Mechanism: Ioflupane binds presynaptic dopamine transporters (DAT) in the striatum (caudate/putamen). SPECT distinguishes neurodegenerative Parkinsonian syndromes (reduced striatal binding) from essential tremor or drug-induced Parkinsonism patterns when clinically appropriate.

  • Item Teaching points
  • Nuclide / energy I-123; 159 keV
  • Admin IV
  • Typical adult activity ~3–5 mCi (111–185 MBq) common teaching range
  • Imaging SPECT typically 3–6 hours after injection
  • Thyroid blockade Yes—block free iodide before injection

Critical med holds: drugs that bind DAT or alter dopamine terminals can invalidate interpretation—classically cocaine, amphetamines, methylphenidate , and selected other agents per insert. Do not tell patients that all Parkinson medications must always be stopped—follow the ordered hold list; many levodopa regimens continue. Prep traps: no blockade (thyroid visualization), motion on SPECT, and interpreting without clinical correlation.

Indium-111 Diagnostic Family

In-111 decays by electron capture with principal gammas near 171 keV and 245 keV and a physical half-life of about 2.8 days —ideal for 24–72 hour delayed imaging.

Product Mechanism Classic indications Notes

In-111 chloride Source material / labeling precursor Component for labeling workflows Not a routine free “scan agent” by itself in most clinics

In-111 oxine WBCs Lipophilic oxine labels leukocytes ; cells migrate to infection Osteomyelitis, abscess, FUO, prosthesis infection workups Compare with Tc-99m HMPAO WBCs; longer t½ favors delayed imaging; dual-isotope with sulfur colloid for marrow

In-111 DTPA CSF tracer after intrathecal injection Cisternography , CSF leak, shunt patency (protocol-specific) Never confuse with IV renal DTPA (Tc-99m); route is critical

In-111 pentetreotide (Octreoscan®) Somatostatin receptor (SSTR) binding (mainly subtype 2) Neuroendocrine tumors historically Increasingly displaced by Ga-68 DOTA-peptide PET, but still tested

WBC Labeling Safety (In-111 oxine)

Same non-negotiables as Tc-labeled cells: positive patient ID, aseptic technique, adequate leukocyte harvest, remove unbound indium, assay labeling efficiency, and reinject only the donor . Image often at ~4 h and 24 h (sometimes later). Damaged cells sequester in lungs/liver/spleen and create false patterns.

Octreoscan Prep Notes

Hold short-acting somatostatin analogs per protocol (long-acting depot timing is specially scheduled). Hydrate; laxatives sometimes used to clear gut activity. Bowel activity is a classic interpretation trap—delayed imaging and SPECT help.

Comparison Snapshot

  • Clinical goal Preferred agent (this section)
  • Thyroid morphology (diagnostic imaging) I-123 NaI
  • Post-thyroidectomy diagnostic whole-body survey I-131 NaI (diagnostic activity)
  • Pheo/neuroblastoma sympathetic imaging I-123 MIBG + thyroid blockade
  • DAT SPECT (Parkinsonian workup) I-123 ioflupane (DaTscan®)
  • Labeled WBC infection (In product) In-111 oxine WBCs
  • Cisternography / CSF In-111 DTPA (intrathecal)
  • SSTR SPECT (legacy/available) In-111 pentetreotide

Memorize 159 keV / 13 h for I-123 products, 364 keV / 8 d for I-131, and 171+245 keV / 2.8 d for In-111—then attach mechanism and prep.